Results 51 to 60 of about 143,709 (342)
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES
Медицинская иммунология, 2014 . Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics.
A. L. Masliansky +4 more
doaj +1 more source
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
Haematologica, 2020 The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or obinutuzumab improved the therapy of B-cell malignancies even though the precise physiological role and regulation of CD20 remains unclear. Furthermore, CD20 expression
Gabriela Pavlasova, Marek Mraz
doaj +1 more source
CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
Frontiers in Oncology, 2022 ObjectiveTranslocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression is uncommon in MM while strongly associated with t(11;14).
Yuan Jian +7 more
doaj +1 more source
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]
, 2009 The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core +2 more sources
Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]
, 2016 With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S. +6 more
core +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang +8 more
wiley +1 more source
Anti-CD20 monoclonal antibodies: reviewing a revolution
Human Vaccines & Immunotherapeutics, 2018 Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice.
J. M. L. Casan +3 more
doaj +1 more source
Phylogenetic Analysis of Cell Types using Histone Modifications
, 2013 In cell differentiation, a cell of a less specialized type becomes one of a more specialized type, even though all cells have the same genome. Transcription factors and epigenetic marks like histone modifications can play a significant role in the ...
Bucher, Philipp +3 more
core +1 more source
Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients [PDF]
, 2015 Natural Killer (NK) cells are a key component of tumor immunosurveillance and thus play an important role in rituximab-dependent killing of lymphoma cells via an antibody-dependent cellular cytotoxicity (ADCC) mechanism.
Battella, Simone +13 more
core +1 more source